WT1 and ACE mRNAs of blood extracellular vesicle as biomarkers of diabetic nephropathy.
ACE
Biomarker
Diabetic nephropathy
ELMO1
Extracellular vesicle
WT1
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
10 07 2021
10 07 2021
Historique:
received:
30
01
2021
accepted:
27
06
2021
entrez:
11
7
2021
pubmed:
12
7
2021
medline:
6
8
2021
Statut:
epublish
Résumé
Diabetic nephropathy (DN) has an increasing global prevalence with excessive health expenditure and burden. Exosomal mRNAs regulate intercellular communications and participate in the pathogenesis of various disorders like DN. This study aimed to assess the expression levels of ACE, ELMO1, and WT1 mRNAs in the blood extracellular vesicles (EVs) of DN patients and diabetic patients without nephropathy (DM group) in comparison to healthy controls and investigate their correlations with the severity of DN. The performed investigation is a cross-sectional study of 256 participants including 103 DN patients, 100 DM patients, and 53 healthy controls. The quantification of WT1, ACE, and ELMO1 mRNAs in the blood EVs were executed using qRT-PCR. The ROC analysis was performed to determine the diagnostic accuracy of mRNAs. DN patients had significantly higher expressed WT1 mRNA (1.70-fold change) and lower expressed ACE mRNA (0.55-fold change) in the blood EVs compared to DM patients and controls. ELMO1 mRNA was not expressed in EVs of any groups. A positive correlation between WT1 mRNA level and urine Alb/Cr ratio (r = 0.602, p < 0.001) and a negative correlation between ACE mRNA expression and urine Alb/Cr ratio within DN patients (r = - 0.474, p < 0.001) was identified. The accuracy of WT1 mRNA and 1/ACE mRNA for predicting incipient DN was 0.63 (95% CI 0.55, 0.72) and 0.62 (95% CI 0.54, 0.71), and for predicting overt DN was 0.83 (95% CI 0.74, 0.92) and 0.75 (95% CI 0.66, 0.83), respectively. WT1 and ACE mRNAs level in blood EVs were predictors for early diagnosis of DN therefore their quantifications might be used to determine the severity of albuminuria and glomerular injuries.
Sections du résumé
BACKGROUND
Diabetic nephropathy (DN) has an increasing global prevalence with excessive health expenditure and burden. Exosomal mRNAs regulate intercellular communications and participate in the pathogenesis of various disorders like DN. This study aimed to assess the expression levels of ACE, ELMO1, and WT1 mRNAs in the blood extracellular vesicles (EVs) of DN patients and diabetic patients without nephropathy (DM group) in comparison to healthy controls and investigate their correlations with the severity of DN.
METHODS
The performed investigation is a cross-sectional study of 256 participants including 103 DN patients, 100 DM patients, and 53 healthy controls. The quantification of WT1, ACE, and ELMO1 mRNAs in the blood EVs were executed using qRT-PCR. The ROC analysis was performed to determine the diagnostic accuracy of mRNAs.
RESULTS
DN patients had significantly higher expressed WT1 mRNA (1.70-fold change) and lower expressed ACE mRNA (0.55-fold change) in the blood EVs compared to DM patients and controls. ELMO1 mRNA was not expressed in EVs of any groups. A positive correlation between WT1 mRNA level and urine Alb/Cr ratio (r = 0.602, p < 0.001) and a negative correlation between ACE mRNA expression and urine Alb/Cr ratio within DN patients (r = - 0.474, p < 0.001) was identified. The accuracy of WT1 mRNA and 1/ACE mRNA for predicting incipient DN was 0.63 (95% CI 0.55, 0.72) and 0.62 (95% CI 0.54, 0.71), and for predicting overt DN was 0.83 (95% CI 0.74, 0.92) and 0.75 (95% CI 0.66, 0.83), respectively.
CONCLUSIONS
WT1 and ACE mRNAs level in blood EVs were predictors for early diagnosis of DN therefore their quantifications might be used to determine the severity of albuminuria and glomerular injuries.
Identifiants
pubmed: 34246281
doi: 10.1186/s12967-021-02964-6
pii: 10.1186/s12967-021-02964-6
pmc: PMC8272332
doi:
Substances chimiques
Adaptor Proteins, Signal Transducing
0
Biomarkers
0
ELMO1 protein, human
0
RNA, Messenger
0
WT1 Proteins
0
WT1 protein, human
0
ACE protein, human
EC 3.4.15.1
Peptidyl-Dipeptidase A
EC 3.4.15.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
299Informations de copyright
© 2021. The Author(s).
Références
Front Immunol. 2020 Jun 03;11:943
pubmed: 32582146
Diabetes Care. 2020 Jan;43(Suppl 1):S14-S31
pubmed: 31862745
Philos Trans R Soc Lond B Biol Sci. 2014 Sep 26;369(1652):
pubmed: 25135963
Saudi J Kidney Dis Transpl. 2012 Sep;23(5):993-9
pubmed: 22982912
Diabetes Care. 2015 Jun;38(6):954-62
pubmed: 25998286
Sci Rep. 2020 Oct 23;10(1):18209
pubmed: 33097787
Noncoding RNA Res. 2020 Apr 11;5(2):71-76
pubmed: 32346662
J Transl Med. 2018 May 30;16(1):146
pubmed: 29848325
Am Fam Physician. 2012 May 1;85(9):883-9
pubmed: 22612183
J Clin Invest. 2016 Apr 1;126(4):1152-62
pubmed: 27035807
PLoS One. 2016 Jan 26;11(1):e0147329
pubmed: 26812415
J Transl Med. 2019 Jul 22;17(1):236
pubmed: 31331349
J Transl Med. 2019 Aug 13;17(1):264
pubmed: 31409386
Prog Lipid Res. 2017 Apr;66:30-41
pubmed: 28342835
J Clin Med. 2020 Apr 23;9(4):
pubmed: 32340338
Nat Rev Nephrol. 2016 Feb;12(2):73-81
pubmed: 26553517
J Biol Chem. 1987 Jul 5;262(19):9412-20
pubmed: 3597417
Curr Opin Nephrol Hypertens. 2011 May;20(3):246-57
pubmed: 21422923
Ann Hum Genet. 2016 Nov;80(6):336-341
pubmed: 27699784
Cell. 2019 Apr 4;177(2):428-445.e18
pubmed: 30951670
J Control Release. 2019 Aug 28;308:119-129
pubmed: 31325471
Clin J Am Soc Nephrol. 2017 Dec 7;12(12):2032-2045
pubmed: 28522654
N Engl J Med. 2001 Sep 20;345(12):870-8
pubmed: 11565519
J Transl Med. 2018 Oct 25;16(1):292
pubmed: 30359254
Science. 2020 Feb 7;367(6478):
pubmed: 32029601
J Diabetes Metab Disord. 2016 Oct 7;15:43
pubmed: 27761430
Diabetes Res Clin Pract. 2017 Jun;128:40-50
pubmed: 28437734
Sci Rep. 2016 Nov 16;6:37172
pubmed: 27849017
J Med Invest. 2018;65(3.4):208-215
pubmed: 30282862
Diabetes Metab Res Rev. 2014 Nov;30(8):736-41
pubmed: 24687388
Cancer Res. 2017 Dec 1;77(23):6480-6488
pubmed: 29162616
J Diabetes Res. 2016;2016:7932765
pubmed: 26942205
J Transl Med. 2019 Feb 28;17(1):59
pubmed: 30819181
J Investig Med. 2020 Mar;68(3):748-755
pubmed: 31722957